Top

BMC Cancer

Published in:

Open Access 01-12-2006 | Research article

Effects of polymorphisms in ERCC1, ASE-1 and RAIon the risk of colorectal carcinomas and adenomas: a case control study

Authors: Camilla F Skjelbred, Mona Sæbø, Bjørn A Nexø, Håkan Wallin, Inger-Lise Hansteen, Ulla Vogel, Elin H Kure

Published in: BMC Cancer | Issue 1/2006

Abstract

Background

The risk of sporadic colorectal cancer is mainly associated with lifestyle factors and may be modulated by several genetic factors of low penetrance. Genetic variants represented by single nucleotide polymorphisms in genes encoding key players in the adenoma carcinoma sequence may contribute to variation in susceptibility to colorectal cancer. In this study, we aimed to evaluate whether the recently identified haplotype encompassing genes of DNA repair and apoptosis, is associated with increased risk of colorectal adenomas and carcinomas.

Methods

We used a case-control study design (156 carcinomas, 981 adenomas and 399 controls) to test the association between polymorphisms in the chromosomal region 19q13.2-3, encompassing the genes ERCC1, ASE-1 and RAI, and risk of colorectal adenomas and carcinomas in a Norwegian cohort. Odds ratio (OR) and 95% confidence interval (CI) were estimated by binary logistic regression model adjusting for age and gender.

Results

The ASE-1 polymorphism was associated with an increased risk of adenomas, OR of 1.39 (95% CI 1.06–1.81), which upon stratification was apparent among women only, OR of 1.66 (95% CI 1.15–2.39). The RAI polymorphism showed a trend towards risk reduction for both adenomas (OR of 0.70, 95% CI 0.49–1.01) and carcinomas (OR of 0.49, 95% CI 0.21–1.13) among women, although not significant. Women who were homozygous carriers of the high risk haplotype had an increased risk of colorectal cancer, OR of 2.19 (95% CI 0.95–5.04) compared to all non-carriers although the estimate was not statistically significant.

Conclusion

We found no evidence that the studied polymorphisms were associated with risk of adenomas or colorectal cancer among men, but we found weak indications that the chromosomal region may influence risk of colorectal cancer and adenoma development in women.

Available only for authorised users

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319 (9): 525-532.CrossRefPubMed

Potter JD: Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999, 91 (11): 916-932. 10.1093/jnci/91.11.916.CrossRefPubMed

De Jong MM, Nolte IM, Te Meerman GJ, Van Der Graaf WT, De Vries EG, Sijmons RH, Hofstra RM, Kleibeuker JH: Low-penetrance Genes and Their Involvement in Colorectal Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev. 2002, 11 (11): 1332-1352.PubMed

Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA: Haplotype tagging for the identification of common disease genes. Nat Genet. 2001, 29 (2): 233-237. 10.1038/ng1001-233.CrossRefPubMed

Yin J, Rockenbauer E, Hedayati M, Jacobsen NR, Vogel U, Grossman L, Bolund L, Nexo BA: Multiple single nucleotide polymorphisms on human chromosome 19q13.2-3 associate with risk of Basal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2002, 11 (11): 1449-1453.PubMed

Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, Wallin H, Overvad K, Tjonneland A: A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis. 2003, 24 (5): 899-904. 10.1093/carcin/bgg043.CrossRefPubMed

Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A, Bukowy Z, Wallin H, Overvad K, Tjonneland A, Nexo BA, Raaschou-Nielsen O: Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res. 2004, 546 (1–2): 65-74.CrossRefPubMed

Laska MJ, Nexo BA, Vistisen K, Poulsen HE, Loft S, Vogel U: Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer. Cancer Lett. 2005, 225 (2): 245-251. 10.1016/j.canlet.2005.03.021.CrossRefPubMed

van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken HM, Hoeijmakers JH, Bootsma D: Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell. 1986, 44 (6): 913-923. 10.1016/0092-8674(86)90014-0.CrossRefPubMed

10.

Wood RD: Nucleotide excision repair in mammalian cells. J Biol Chem. 1997, 272 (38): 23465-23468. 10.1074/jbc.272.38.23465.CrossRefPubMed

11.

Whitehead CM, Winkfein RJ, Fritzler MJ, Rattner JB: ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes. Chromosoma. 1997, 106 (8): 493-502. 10.1007/s004120050271.CrossRefPubMed

12.

Yamamoto K, Yamamoto M, Hanada K, Nogi Y, Matsuyama T, Muramatsu M: Multiple protein-protein interactions by RNA polymerase I-associated factor PAF49 and role of PAF49 in rRNA transcription. Mol Cell Biol. 2004, 24 (14): 6338-6349. 10.1128/MCB.24.14.6338-6349.2004.CrossRefPubMedPubMedCentral

13.

Yang JP, Hori M, Sanda T, Okamoto T: Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem. 1999, 274 (22): 15662-15670. 10.1074/jbc.274.22.15662.CrossRefPubMed

14.

Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50–64 years. Scand J Gastroenterol. 2003, 38 (6): 635-642. 10.1080/00365520310003002.CrossRefPubMed

15.

ClinicalTrials.gov. [http://www.clinicaltrials.gov]

16.

Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16 (3): 1215-CrossRefPubMedPubMedCentral

17.

Hansen R, Saebo M, Skjelbred CF, Nexo BA, Hagen PC, Bock G, Bowitz Lothe IM, Johnson E, Aase S, Hansteen IL, Vogel U, Kure EH: GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005, 229 (1): 85-91. 10.1016/j.canlet.2005.04.019.CrossRefPubMed

18.

Rockenbauer E, Bendixen MH, Bukowy Z, Yin J, Jacobsen NR, Hedayati M, Vogel U, Grossman L, Bolund L, Nexo BA: Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts. Carcinogenesis. 2002, 23 (7): 1149-1153. 10.1093/carcin/23.7.1149.CrossRefPubMed

19.

Vogel U, Hedayati M, Dybdahl M, Grossman L, Nexo BA: Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis. 2001, 22 (6): 899-904. 10.1093/carcin/22.6.899.CrossRefPubMed

20.

Vogel U, Olsen A, Wallin H, Overvad K, Tjonneland A, Nexo BA: Effect of polymorphisms in XPD, RAI, ASE-1 and ERCC1 on the risk of basal cell carcinoma among Caucasians after age 50. Cancer Detect Prev. 2005, 29 (3): 209-214. 10.1016/j.cdp.2005.01.001.CrossRefPubMed

21.

Vogel U, Sorensen M, Hansen R, Tjonneland A, Overvad K, Wallin H, Nexo B, Raaschou-Nielsen O: Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett. 2006,

22.

Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X: iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003, 33 (2): 162-167. 10.1038/ng1070.CrossRefPubMed

23.

Zhang X, Wang M, Zhou C, Chen S, Wang J: The expression of iASPP in acute leukemias. Leuk Res. 2005, 29 (2): 179-183. 10.1016/j.leukres.2004.07.001.CrossRefPubMed

24.

Vogel U, Nexo BA, Tjonneland A, Wallin H, Hertel O, Raaschou-Nielsen O: ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes. Mutat Res. 2006, 593 (1–2): 88-96.CrossRefPubMed

25.

Yamazaki T, Hamano Y, Tashiro H, Itoh K, Nakano H, Miyatake S, Saito T: CAST, a novel CD3epsilon-binding protein transducing activation signal for interleukin-2 production in T cells. J Biol Chem. 1999, 274 (26): 18173-18180. 10.1074/jbc.274.26.18173.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/175/prepub

Title: Effects of polymorphisms in ERCC1, ASE-1 and RAIon the risk of colorectal carcinomas and adenomas: a case control study
Authors: Camilla F Skjelbred
Mona Sæbø
Bjørn A Nexø
Håkan Wallin
Inger-Lise Hansteen
Ulla Vogel
Elin H Kure
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-6-175

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2006

ATM variants and cancer risk in breast cancer patients from Southern Finland

Hypoxia-inducible transcription factor-1α promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway

Association between dietary fat and skin cancer in an Australian population using case-control and cohort study designs

Homeostatic response under carcinogen withdrawal, heme oxygenase 1 expression and cell cycle association

BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility

Health profiles of 996 melanoma survivors: the M. D. Anderson experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer